{"entity":{"id":"nct05859217","kind":"trial","name":"A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)","aka":["Cabatezo-1"],"tldr":"A phase 2 trial of cabozantinib and atezolizumab in lung cancer, run by Jun Zhang, MD, PhD, not yet recruiting.","summary":"A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) is a phase 2, interventional study registered as NCT05859217 by Jun Zhang, MD, PhD, with a registry enrolment figure of 40 participants, started 2024-12 and due to reach its primary completion in 2026-06. Interventions recorded: Cabozantinib; Atezolizumab. Conditions listed: Lung Cancer; NSCLC Stage IV; Metastatic NSCLC - Non-Small Cell Lung Cancer; Advanced NSCLC. Primary outcome: Objective response rate (ORR). Lung eligibility wording from the registry: \"* Pathologically confirmed advanced/metastatic NSCLC, with PD-L1\\<1% based on IHC using 22C3 antibody\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT05859217","url":"https://clinicaltrials.gov/study/NCT05859217"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["cabozantinib","atezolizumab"],"companies":["exelixis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05859217","phase":"2","setting":"A Multi-center Phase II Study of Combining Cabozantinib and Atezolizumab as the 1st Line Therapy for PD-L1 Negative Advanced/Metastatic NSCLC (Cabatezo-1)","sponsor":"Jun Zhang, MD, PhD","enrolled":40,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05859217/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"cabozantinib","kind":"drug","name":"Cabozantinib","route":"/drugs/cabozantinib/"}],"company":[{"id":"exelixis","kind":"company","name":"Exelixis","route":"/companies/exelixis/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}